Previous 10 | Next 10 |
Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-202...
SOS Limited (SOS) +66%.Future FinTech Group (FTFT) +32% after CCPC accepted the Company's application for ten software copyrights.CBAK Energy Technology (CBAT) +39%.The9 Limited (NCTY) +35%.Xunlei Limited (XNET) +31%.Oxford Immunotec Global PLC (OXFD) +27% as PerkinElmer to acquire ...
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Ener...
Cowen Washington Research Group analyst Jaret Seiberg weighs in the shockwaves in the cannabis sector from the Georgia Senate runoff elections. Sienerg thinks the STATES Act is most likely of the pending legislation as it could move regardless of what happens to the filibuster. He says the MO...
TAT Technologies (TATT) +37% after signing strategic agreement with Honeywell.Change Healthcare Inc. (CHNG) +35% as UnitedHealth to acquire the company for $25.75 in cash.DBV Technologies S.A. (DBVT) +19%.Aurora Cannabis (ACB) +17% on possible Georgia 'blue sweep'.HEXO (HEXO) +17%...
A huge day is setting up for the cannabis sector as investors size up the impact of the Georgia Senate election on future legislation.Double-digit gainers in premarket action include Sundial Growers (SNDL) +18.44%, HEXO (HEXO) +17.44%, Orchard Therapeutics (ORTX) +15.44% and Greenlane Holding...
BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday January 13, 2021 at 9:10 AM...
Orchard Therapeutics (ORTX) +4% premarket, after the European Commission ((EC)) approves Libmeldy, gene therapy for the treatment of metachromatic leukodystrophy ((MLD)), a rare genetic condition caused by mutations in the ARSA gene, characterized by accumulation of f...
First gene therapy to receive full EU marketing authorization for eligible MLD patients One-time treatment with Libmeldy has been shown to preserve motor and cognitive function Achievement shared with research alliance partners Fondazione Telethon and Ospedale San R...
Today, we take a look at Orchard Therapeutics, a developmental concern from across the pond that has discernible potential catalysts on the horizon. With a couple of drug candidates in late-stage development, this is an intriguing name in the gene therapy space. Orchard will be ad...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....